INVA logo

Innoviva (INVA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 October 2004

Indexes:

Not included

Description:

Innoviva, also known as INVA, is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. They aim to improve patient outcomes through advanced treatments and partnerships, working to address unmet medical needs in the healthcare market.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 06, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Sept 08, 2015
Splits

Next split:

N/A

Recent split:

June 03, 2014

Analyst ratings

Recent major analysts updates

01 Aug '24 Cantor Fitzgerald
Overweight
30 July '24 Cantor Fitzgerald
Overweight
20 June '24 Cantor Fitzgerald
Overweight
18 June '24 Cantor Fitzgerald
Overweight
10 May '23 EF Hutton
Buy
20 Apr '23 EF Hutton
Buy
03 Mar '23 Morgan Stanley
Underweight
03 Mar '23 Goldman Sachs
Neutral
03 Mar '23 EF Hutton
Buy
24 Jan '23 Morgan Stanley
Underweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
INVA
globenewswire.com16 December 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. (NASDAQ: INVA), for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States (US).

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
INVA
businesswire.com20 May 2024

Zai Lab Limited and Innoviva Specialty Therapeutics have received approval from China's NMPA for Zai Lab's NDA for XACDURO® (sulbactam-durlobactam) for the treatment of HABP/VABP caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus comp.

Innoviva: A Lot Of Moving Parts
Innoviva: A Lot Of Moving Parts
Innoviva: A Lot Of Moving Parts
INVA
Seeking Alpha09 October 2023

Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it receives from Glaxo Group Limited. There has been a lot of movement at the company over the past 12-18 months on myriad fronts.

FDA approves Innoviva's bacterial pneumonia treatment
FDA approves Innoviva's bacterial pneumonia treatment
FDA approves Innoviva's bacterial pneumonia treatment
INVA
Market Watch23 May 2023

The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.

Is Innoviva (INVA) Stock Undervalued Right Now?
Is Innoviva (INVA) Stock Undervalued Right Now?
Is Innoviva (INVA) Stock Undervalued Right Now?
INVA
Zacks Investment Research17 April 2023

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

FAQ

  • What is the primary business of Innoviva?
  • What is the ticker symbol for Innoviva?
  • Does Innoviva pay dividends?
  • What sector is Innoviva in?
  • What industry is Innoviva in?
  • What country is Innoviva based in?
  • When did Innoviva go public?
  • Is Innoviva in the S&P 500?
  • Is Innoviva in the NASDAQ 100?
  • Is Innoviva in the Dow Jones?
  • When was Innoviva's last earnings report?
  • When does Innoviva report earnings?
  • Should I buy Innoviva stock now?

What is the primary business of Innoviva?

Innoviva, also known as INVA, is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. They aim to improve patient outcomes through advanced treatments and partnerships, working to address unmet medical needs in the healthcare market.

What is the ticker symbol for Innoviva?

The ticker symbol for Innoviva is NASDAQ:INVA

Does Innoviva pay dividends?

No, Innoviva does not pay dividends

What sector is Innoviva in?

Innoviva is in the Healthcare sector

What industry is Innoviva in?

Innoviva is in the Biotechnology industry

What country is Innoviva based in?

Innoviva is headquartered in United States

When did Innoviva go public?

Innoviva's initial public offering (IPO) was on 05 October 2004

Is Innoviva in the S&P 500?

No, Innoviva is not included in the S&P 500 index

Is Innoviva in the NASDAQ 100?

No, Innoviva is not included in the NASDAQ 100 index

Is Innoviva in the Dow Jones?

No, Innoviva is not included in the Dow Jones index

When was Innoviva's last earnings report?

Innoviva's most recent earnings report was on 6 November 2024

When does Innoviva report earnings?

The next expected earnings date for Innoviva is 28 February 2025

Should I buy Innoviva stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions